Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pyrrolidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.50 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.50 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL28547040 | 1.00 | ALDH1A1 (0.80) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Pyrrolidine SCHEMBL724812 | 1.00 | — | — | |
| Pyrrolidine SCHEMBL996579 | 1.00 | ALDH1A1 (0.80) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Pyrrolidine SCHEMBL29194307 | 0.95 | — | — | |
| Piperidine SCHEMBL7575329 | 0.95 | ALDH1A1 (0.90) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL4616564 | 0.95 | — | — | |
| Pyrrolidine SCHEMBL28458206 | 0.95 | — | — | |
| Azepane SCHEMBL20563677 | 0.95 | — | — | |
| Piperidine SCHEMBL7575332 | 0.95 | — | — | |
| Piperidine SCHEMBL781392 | 0.95 | ALDH1A1 (0.90) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179081-A1 | COMPOUND AND PRODUCTION METHOD THEREOF, AFX-TYPE ZEOLITE AND PRODUCTION METHOD THEREOF, AND HONEYCOMB STACKED CATALYST | OSAKA UNIVERSITY (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250025855-A1 | EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF | ExxonMobil Technology and Engineering Company | 2025-01-23 | — | — | US | disclosed |
| US-20250025854-A1 | EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF | ExxonMobil Technology and Engineering Company | 2025-01-23 | — | — | US | disclosed |
| US-12161990-B2 | EMM-41 composition, methods of making and uses thereof | ExxonMobil Technology and Engineering Company (US) | 2024-12-10 | — | — | US | disclosed |
| CN-113165893-B | EMM-41 compositions, methods of manufacture and uses thereof | 埃克森美孚科技工程公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3597293-B1 | TRANSITION METAL-CARRYING ZEOLITE AND PRODUCTION METHOD THEREFOR, AND NITROGEN OXIDE PURIFICATION CATALYST AND METHOD FOR USING SAME | MITSUBISHI CHEM CORP (JP) | 2023-07-26 | — | — | EP | disclosed |
| US-20230219822-A1 | PHOSPHORUS ELEMENT-CONTAINING ZEOLITE AND METHOD FOR PRODUCING PHOSPHORUS ELEMENT-CONTAINING ZEOLITE | N.E. CHEMCAT CORPORATION (JP) | 2023-07-13 | — | — | US | disclosed |
| US-11400421-B2 | Method of producing zeolite membrane complex and zeolite membrane complex | NGK INSULATORS, LTD. (JP) | 2022-08-02 | — | — | US | disclosed |
| US-20220213110-A1 | COMPOUND AND PRODUCTION METHOD THEREOF, AFX-TYPE ZEOLITE AND PRODUCTION METHOD THEREOF, AND HONEYCOMB STACKED CATALYST | OSAKA UNIVERSITY (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20220023827-A1 | EMM-41 Composition, Methods of Making and Uses Thereof | EXXONMOBIL RES & ENG CO (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3894355-A2 | EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF | ExxonMobil Research and Engineering Company (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-113165893-A | EMM-41 compositions, methods of manufacture, and uses thereof | 埃克森美孚研究工程公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020123070-A2 | EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2020-06-18 | — | — | WO | disclosed |
| US-7582278-B2 | Microporous crystalline zeolite material, zeolite ITQ-32, preparation method thereof and use of same | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2009-09-01 | — | — | US | disclosed |
| US-20090068092-A1 | Microporous Crystalline Zeolite Material, Zeolite ITQ-32, Preparation Method Thereof and Use of Same | UNIVERSIDAD POLITECNICA DE VALENCIA (ES) | 2009-03-12 | — | — | US | disclosed |
| EP-1852394-A1 | MICROPOROUS CRYSTALLINE ZEOLITE MATERIAL, ZEOLITE ITQ-32, PREPARATION METHOD THEREOF AND USE OF SAME | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023827-A1 | EMM-41 Composition, Methods of Making and Uses Thereof | CD14, CD68, MASP2 | PDE4A 3755/4885KDR 1161/4885MEN1 52/4885 |
| US-20220213110-A1 | COMPOUND AND PRODUCTION METHOD THEREOF, AFX-TYPE ZEOLITE AND PRODUCTION METHOD THEREOF, AND HONEYCOMB STACKED CATALYST | SFXN1, NFXL1, MLX | PDE4A 4293/4885KDR 4443/4885MEN1 496/4885 |
| US-20250025855-A1 | EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF | CD14, CD68, MASP2 | PDE4A 3755/4885KDR 1161/4885MEN1 52/4885 |
| US-12161990-B2 | EMM-41 composition, methods of making and uses thereof | CD14, CD68, MASP2 | PDE4A 3755/4885KDR 1161/4885MEN1 52/4885 |
| US-20250179081-A1 | COMPOUND AND PRODUCTION METHOD THEREOF, AFX-TYPE ZEOLITE AND PRODUCTION METHOD THEREOF, AND HONEYCOMB STACKED CATALYST | SFXN1, NFXL1, MLX | PDE4A 4245/4885KDR 4431/4885MEN1 455/4885 |
| US-20250025854-A1 | EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF | CD14, CD68, MASP2 | PDE4A 3755/4885KDR 1161/4885MEN1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.